Introduction
Respiratory syncytial virus (RSV) is a pneumovirus of the family Paramyxoviridae and is the major cause of severe lower respiratory tract infections in children and calves during the first year of life (Kim et al., 1973; Stott et al., 1980) . Human and bovine strains of RSV are antigenically distinct, but closely related (Lerch et al., 1989) , the antigenic differences residing mainly on the attachment protein (Lerch et al., 1990) . Difficulties have been encountered with the use of both live and inactivated vaccines in children and calves. Live vaccines are not effective in the age group of children or calves most at risk because of the immunosuppressive effect of maternal antibody (Belshe et al., 1982; Zygraich, 1982) ; a formalin-inactivated RSV vaccine administered to children not only failed to protect against RSV infection but exacerbated the respiratory disease (Fulginiti et al., 1969) . It has been suggested that formalin inactivation modifies some of the epitopes on RSV proteins so that immunization results in the production of non-functional antibodies which may contribute to an Arthus reaction. However, exacerbation of respiratory disease has also been observed in calves given a live RSV vaccine (Kimman et al., 1989) and in small laboratory animals immunized with recombinant virus vaccines which did protect against infection (Stott et al., 1987) . These findings highlight the need to identify the protective epitopes on RSV proteins and the immune effector mechanisms that protect against infection. The fusion (F) glycoprotein of RSV has been identified as the most important antigen in inducing cross-protective immunity (Olmsted et al., 1986; Stott et al., 1987) and monoclonal antibodies (MAbs) to this protein are highly effective both in preventing RSV infection and in clearing an established infection (Walsh et al., 1984; Taylor et al., 1984a; Tempest et al., 1991) .
The F protein of RSV mediates fusion of the virus with cell membranes, and fusion of infected cells with adjacent uninfected cells. The nucleotide sequence of the F protein has been determined (Collins et al., 1984; Elango et al., 1985) and encodes a protein of 574 amino acids. There is a high degree of genetic and antigenic homology between the F protein of human and bovine strains of RSV (Lerch et al., 1989) . The protein is posttranslationally modified by glycosylation and proteolytically cleaved to yield two disulphide-linked subunits, designated F1 and F2. The N terminus of F1 is hydrophobic and is thought to initiate fusion by interacting directly with the host cell membrane. Several laboratories have identified antigenic sites on the F protein using a variety of methods. Competitive binding assays with murine MAbs have identified three neutralizing epitopes on the F pl:otein, two of which are also fusion-inhibiting (FI) (Walsh et al., 1986; Trudel et al., 1987a; Beeler & van Wyke Coelingh, 1989 (Trudel et al., 1987b; Bourgeois et al., 1991 ; Paradiso et al., 1991; Scopes et al., 1990) . Isolation of antibodyescape mutants and sequence analysis of the F protein of the mutants has been used to identify the amino acid residues important for the binding of neutralizing MAbs (Lopez et al., 1990) .
To identify protective epitopes on the F protein recognized by a natural host of RSV, we produced 10 bovine MAbs to this protein and examined their ability to protect mice against RSV infection. Using these antibodies together with 16 murine MAbs we have mapped the epitopes on the F protein recognized by the protective MAbs by two methods: (i) competitive binding assay, and (ii) binding of the MAbs to antibodyescape mutants.
Methods
Viruses. The A2 strain of human RSV belongs to subtype A and was isolated from a child in Australia (Lewis et al., 1961) . A human B subtype (8/60) was obtained from the Common Cold Unit, Salisbury, U.K. Both human strains of RSV were grown in HEp-2 cells. The 127 strain of bovine RSV was isolated at Compton in 1973 from a calf with respiratory disease and was grown in secondary calf kidney (CK) cells.
Preparation of MAbs.
Murine MAbs 1 to 14 have been described previously (Taylor et al., 1984a) , and were produced by immunizing BALB/c mice with either bovine RSV strain 127 or with cells persistently infected with the Long strain of human RSV (Fernie et al., 1981) . Murine MAbs 16 to 21 were produced from BALB/c mice inoculated intranasaUy (i.n.) on two occasions, 3 weeks apart, with 1 x 104 p.f.u, of the A2 strain of RSV. After an interval of 4 months, the mice were inoculated intraperitoneally (i.p.) with 2 x l0 T p.f.u, of the 127 strain of bovine RSV. Three days after the booster inoculation, immune splenocytes were fused with NS-1 myeloma cells. The resulting hybridomas were screened for antibody to RSV by radioimmunoassay and immunofluorescence and cloned twice on soft agar, and cloned cells were inoculated into BALB/c mice to produce ascitic fluid as described previously (Taylor et al., 1984a) .
Bovine MAbs B1 to B6 have been described previously (Kennedy et al., 1988) ; MAbs B7 to B10 were produced from the same animal but using lymphocytes that had been stored in liquid N 2 before fusion with NS-1 cells. Cloned heterohybridoma cells were inoculated into pristane-primed nude BALB/c mice to produce ascitic fluid. In some experiments, heterohybridoma cells were grown in serum-free DCCMl medium (Biological Industries) and the antibody was purified from 3 to 41 of cell culture supernatant using Protein G-Sepharose 4 Fast Flow (Pharmacia LKB) as described below.
Characterization of MAbs. The specificity of MAbs for viral polypeptides was determined by radioimmune precipitation of [35S]methionine-or [3H]glucosamine-labelled RSV-infected cell lysates as described previously (Kennedy et al., 1988) , and by immunoblotting (Taketa et al., 1985) . The antigens used in immunoblotting were HEp-2 cells infected with the A2 strain of human RSV or uninfected HEp-2 ceils. Antigens were prepared and treated as described previously (Kennedy et al., 1988) .
The ability of the MAbs to inhibit multinucleated giant cell formation was assayed in MA104 cells 24 h after infection with the A2 strain of RSV. The ability of MAbs to neutralize RSV was assayed by a plaque reduction neutralization test. Details of both assays have been described previously (Kennedy et al., 1988) .
The ability of MAbs to protect against RSV infection was studied in BALB/c mice. Briefly, 100 I11 of ascitic fluid containing the MAbs was injected i.p. into groups of five mice. One day later, the mice were inoculated i.n. with 104 p.f.u, of the A2 strain of RSV. On day 5 of infection, the mice were killed and their lungs assayed for RSV on secondary CK monolayers (Taylor et al., 1984b) .
Purification and labelling of MAbs. The IgG from ascitic fluid containing either murine or bovine MAbs was purified on Protein ASepharose (Pharmacia LKB). The ascitic fluids were mixed with equal volumes of 0.1 M-phosphate buffer pH 8, and passed through a Protein A-Sepharose column with the same buffer. Bound antibodies were eluted with 0.1 M-citrate buffer (pH 6-0 to 3.5). Fractions eluted with low pH buffers were collected in 1 M-Tris-HC1 pH 9-0. IgG from 3 to 4 1 of bovine hybridoma cell culture supernatants was purified on Protein G-Sepharose Fast Flow. Bound antibody was eluted with 0.1 M-glycine pH 2-7, neutralized with 1 M-Tris-HC1 pH 9.0, dialysed against PBS and labelled with ~25I using chloramine T.
Competition binding assay. The epitope specificity of the murine and bovine MAbs to the F protein was analysed by a competition binding assay. A dilution of ~:5I-labelled MAbs determined to give approx. 10000 c.p.m, at 90~ of maximum binding to RSV antigen in a radioimmunoassay, was allowed to react with RSV antigen in the presence of increasing amounts of various unlabelled MAbs to the F protein. An unlabeUed MAb to the nucleoprotein (N) was used as a negative control.
Antibody-escape mutants. Mutant viruses refractory to neutralization by a specific MAb were produced using a plaque reduction technique with the A2 strain of RSV. Thus, for MAbs 19, 20, B4 and B5, confluent monolayers of primary CK cells were infected with the A2 strain of RSV at a multiplicity of 0.2. Starting 24 h after infection and continuing for 3 to 5 days, the culture medium was replaced daily with fresh medium containing 10~ MAb. Virus was harvested when a c.p.e. was apparent. Virus prepared in this way was mixed with an equal volume of the MAb under examination for 1 h at room temperature and inoculated onto CK monolayers in 35 mm multiwell plates (Nunc). After 1 h incubation at 37 °C, the plates were overlaid with medium containing 0.25~ agarose incorporating a 1:10 dilution of the same MAb. Plates were then incubated at 37 °C in 5~ CO2 in air for 7 days before adding the vital stain, 0-3~ 3-(4,5-dimethylthiazoll-2-yl)-2,5-diphenyltetrazolium bromide in 0-15M-NaCI, to the overlay to visualize virus plaques. Putative mutant viruses were removed in agar plugs from plates which contained single plaques, diluted in medium, mixed with an equal volume of MAb and inoculated onto CK cell monolayers as before. Mutant viruses were picked again and inoculated into tubes containing coverslips of calf testis or HEp-2 cells. After 4 to 6 days incubation, the coverslips were removed and stained with the MAb under examination followed by fluorescein isothiocyanate (FITC)-Iabelled rabbit anti-mouse IgG (Sigma) or FITC-labelled rabbit anti-bovine IgG (Sigma). A polyclonal bovine antibody to RSV followed by FITC-labeUed rabbit anti-bovine IgG was used as a positive control. RSV that failed to react with the MAb as judged by immunofluorescence was classed as a mutant and used to produce antigen for ELISA. Mutant viruses refractory to MAb 11 were selected essentially as described above but without prior culture of the virus in cells containing 10% MAb in the supernatant.
ELISA. RSV antigen for ELISA was prepared from HEp-2 cells 3 to 4 days after infection. Cells were scraped into medium, centrifuged at 500 g for 5 min, resuspended in distilled water and treated with 0.5 (w/v) NP40 detergent to yield a cell lysate. Control antigen was made in a similar way using uninfected HEp-2 cells. Microtitre plates were coated with RSV or control antigen diluted in distilled water overnight Table 1 . The properties of all M A b s are s u m m a r i z e d in Fig. 2 and 3 . Seven of the 16 m u r i n e and two of the 10 bovine M A b s neutralized RSV, :four m u r i n e and two bovine M A b s inhibited the formation of multinucleated giant ceils, and the same six M A b s were highly effective in p r e v e n t i n g RSV infection of B A L B / c mice when a d m i n i s t e r e d i.p. 24 h prior to i.n. challenge with the A 2 strain of RSV ( Fig. 1 and 2 ). All antibodies, except m u r i n e M A b s 9 and 10 (Taylor et al., 1984a) and bovine M A b B8, which Were specific for bovine RSV, reacted with both the A2 and 8 / 6 0 strains of h u m a n RSV and with bovine strains of RSV (Taylor et al., 1984a ; K e n n e d y et al., 1988; Table   Fig . 1. Immunoblot of native and denatured antigen probed with MAbs B4 (lanes 1 to 4) and 19 (lanes 5 to 8), followed by HRPconjugated rabbit anti-bovine IgG or goat anti-mouse IgG and 4-chloro-l-naphthol as substrate. RSV A2-infected (odd numbered lanes) and uninfected (even-numbered lanes) HEp-2 cells were either heated to 60 °C in 2% SDS (lanes 3, 4, 7 and 8) or boiled in 2% SDS and 5% (v/v) 2-mercaptoethanol (lanes 1, 2, 5 and 6) before PAGE. Mr markers are also included (lanes M).
Results

Characterization of MAbs
1), indicating that the epitopes recognized by these M A b s were highly conserved a m o n g strains of RSV.
Identification of antigenic areas in the F protein
The epitope specificity of the 16 murine and 10 bovine M A b s to the (Fig. 2 and 3) . Therefore the clustering of epitopes was done on the basis of partial similarities and analysed using the Leukocyte Typing Database IV (Gilks, 1990) . These studies showed that the 16 murine MAbs recognized seven antigenic areas on the F protein (Fig. 2) . MAbs 2 and 5 competed with nearly all of the other murine MAbs. Two highly protective MAbs, 11 and 13, appeared to recognize the same epitope (site B), whereas two other MAbs, 19 and 20, which were also highly protective, were similar to each other but different from MAbs 11 and 13, and mapped to site C.
Most of the 10 bovine MAbs mapped to the same sites as the murine MAbs (Fig. 3) . Murine MAbs 2 and 5 competed with only four of the bovine MAbs (B2, B3, B4 and B6). A neutralizing murine MAb, 14, which mapped to site G in competition studies with the murine MAbs (Fig. 2) , showed a competition profile that was similar to that of bovine MAbs B2, B3 and B6, and therefore was placed in group H (Fig. 3) . The binding of bovine MAbs B1 and B7 was not inhibited by any of the murine MAbs, and MAb B7 appeared to recognize a distinct epitope. The epitopes recognized by two highly protective bovine MAbs, B4 and B5, were similar to each other and to those recognized by two of the highly protective murine MAbs, 11 and 13. MAbs 18, which is partially protective in mice, and B10, which is not protective, also map in this area (site B).
Taken together the murine and bovine MAbs recognized 11 antigenic areas, most of which overlapped extensively. The highly protective, FI, neutralizing MAbs mapped to two sites (areas B and C in Fig. 2) on the F protein. MAbs that neutralized virus but did not have FI activity mapped to three areas (areas B, D and G). However, MAbs which have neither neutralizing nor FI activity also mapped to these areas.
Binding of MAbs to escape mutants of RSV
The highly protective MAbs 11, B4, B5, 19 and 20 were used to select antibody-escape mutants of RSV. Five mutant viruses were isolated independently from the A2 strain of RSV after plaquing in the presence of MAb 11. Eight mutants were isolated independently after culture in the presence of MAb 19, three mutants after culture in the presence on MAb 20, six after culture in the presence of MAb B5 and 10 after culture in the presence of MAb B4. After plaque purification, the mutants were examined in an ELISA against a panel of anti-F protein antibodies. Mutant viruses selected for resistance to MAb 11 lost the capacity to bind not only MAb 11 but also MAbs 13, B4, B5 and 18 and had reduced binding to MAb 7C2 (Trudel et al., 1987a) , when compared with the parent A2 strain of RSV (Fig. 4) . All mutant viruses selected for resistance to either MAb B4 or B5 lost the capacity to bind not only MAb B4 or B5, but also MAbs 11 and 13. However, some mutants selected with MAb B4 (e.g. C4947/5) still bound to MAb B5, but at a greatly reduced level when compared with the A2 strain. As seen for mutants selected for resistance to MAb 11, some MAb B4-and B5-selected mutants showed reduced binding to MAb 7C2, whereas others failed to react with MAb 7C2 (e.g. C4947/5). In contrast to mutants selected with MAb I I, some mutants selected with MAb B4 or B5 still reacted with MAb 18 (e.g. C4947/5, 61 : 19, 61 : 16, 63 :27 and C5014/7). MAb B4-and B5-selected mutants showed either the same, reduced or no binding to MAb B10 when compared with the parent A2 strain.
All mutant viruses selected with MAbs 19 or 20 failed to react only with MAbs 19 and 20 (Fig. 3) . The binding of all other MAbs (results not shown) to all the mutants was the same as that to the parent A2 strain of RSV.
Discussion
A number of murine and bovine MAbs to the F glycoprotein of RSV have been identified which, when administered by the i.n., intravenous or i.p. routes, protect mice and cotton-rats against RSV infection (Taylor et al., 1984a; Walsh et al., 1984; Kennedy et al., 1988) . Such MAbs are also highly effective in clearing an established RSV infection in small laboratory animals (Tempest et al., 1991) . A comparison of the properties of the MAbs indicated that, although all highly protective antibodies have neutralizing activity, there is no correlation between neutralization titre and protection against infection. For example, the neutralization titre of MAbs 14 and 18 is similar to that of MAb 19, but MAbs 14 and 18 are only partially protective (Taylor et al., 1984;  Table  1 ) whereas MAb 19 is completely protective against infection. Similarly, there is no correlation between the ability of the antibody to lyse virus-infected cells in the presence of complement, and protection. For example, MAbs 17, 18 and 21, which lyse virus-infected cells, are only partially protective in vivo, whereas MAb 19, which is highly protective, is not able to lyse virusinfected cells in the presence of complement. The only property that correlates with high levels of protection against infection is the ability to inhibit the formation of multinucleated giant cells. Thus, MAbs 11, 13, 19, 20, B4 and B5 are the only MAbs with FI activity (Fig. 2 and 3 ) and these antibodies are highly effective against RSV infection in mice. The effectiveness of bovine MAbs with FI activity against RSV infection in cattle is under investigation.
Protective epitopes on the F protein of RSV were identified by examining (i) the competition profiles of 16 murine and 10 bovine MAbs in competitive binding assays, and (ii) the binding of the MAbs to antibodyescape mutants. The results obtained with these methods correlated well. Thus, although the competition profiles of the MAbs overlap extensively, protective MAbs 11, 13, B4 and B5 map to the same area (site B), and mutants selected with these antibodies fail to bind only those MAbs recognizing site B. MAbs 7C2 (Trudel et al., 1987a) and 47F (Garcia-Barreno et al., 1989 ) also map to this area ( Fig. 4; These studies have shown that, taken together, the murine and bovine MAbs recognize 11 antigenic areas, most of which overlap extensively. Neutralizing NAbs appear to recognize four areas, two of which are recognized by highly protective FI NAbs. These findings are similar to those of others who have identified three antigenic sites involved in neutralization on the F protein, two of which are involved in FI activity, using murine MAbs (Walsh et al., 1986 , Beeler & van Wyke Coelingh, 1989 . The discrepancy between the number of neutralizing and FI sites may indicate that the mechanisms of virus-cell and cell-cell fusion are different, or that virus neutralization by anti-F protein NAbs in vitro can occur by a mechanism independent of virus-cell fusion, e.g. steric hindrance of virus attachment. These studies have also shown that most of the bovine NAbs recognize epitopes similar to those recognized by the murine NAbs and, of greater importance, that one of the protective antigenic areas (site B, or antigenic area II in Arbiza et al., 1992 ) is recognized by both cattle, which are a natural host for RSV, and mice.
Sequence analysis of the F protein-encoding mRNA of the antibody-escape mutants to identify the amino acid residues important in the binding of the highly protective NAbs, together with information on the binding of the protective NAbs to synthetic peptides, should help to locate the epitopes that they recognize. These studies are described in Arbiza et al. (1992) .
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